RSLS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RSLS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Reshape Lifesciences's annualized ROCE % for the quarter that ended in Dec. 2023 was -147.99%.
The historical data trend for Reshape Lifesciences's ROCE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Reshape Lifesciences Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
ROCE % | Get a 7-Day Free Trial | -222.25 | -72.23 | -177.66 | -111.29 | -277.60 |
Reshape Lifesciences Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
ROCE % | Get a 7-Day Free Trial | -170.12 | -170.36 | -198.00 | -229.72 | -147.99 |
Reshape Lifesciences's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:
ROCE % | = | EBIT | / | ( (Capital Employed | + | Capital Employed) | / count ) |
(A: Dec. 2023 ) | (A: Dec. 2022 ) | (A: Dec. 2023 ) | |||||
= | EBIT | / | ( ( (Total Assets - Total Current Liabilities) | + | (Total Assets - Total Current Liabilities) ) | / count ) | |
(A: Dec. 2023 ) | (A: Dec. 2022 ) | (A: Dec. 2023 ) | |||||
= | -14.639 | / | ( ( (11.142 - 7.481) | + | (10.663 - 3.777) ) | / 2 ) | |
= | -14.639 | / | ( (3.661 | + | 6.886) | / 2 ) | |
= | -14.639 | / | 5.2735 | ||||
= | -277.60 % |
Reshape Lifesciences's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:
ROCE % | = | EBIT (1) | / | ( (Capital Employed | + | Capital Employed) | / count ) |
(Q: Dec. 2023 ) | (Q: Sep. 2023 ) | (Q: Dec. 2023 ) | |||||
= | EBIT | / | ( ( (Total Assets - Total Current Liabilities) | + | (Total Assets - Total Current Liabilities) ) | / count ) | |
(Q: Dec. 2023 ) | (Q: Sep. 2023 ) | (Q: Dec. 2023 ) | |||||
= | -7.58 | / | ( ( (7.827 - 4.469) | + | (10.663 - 3.777) ) | / 2 ) | |
= | -7.58 | / | ( ( 3.358 | + | 6.886 ) | / 2 ) | |
= | -7.58 | / | 5.122 | ||||
= | -147.99 % |
(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Reshape Lifesciences (OTCPK:RSLS) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
Thank you for viewing the detailed overview of Reshape Lifesciences's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.
Thomas Stankovich | officer: Chief Financial Officer | 1001 CALLE AMANECER, SAN CLEMENTE CA 92673 |
Barton P. Bandy | officer: President and CEO | 1001 CALLE AMANECER, SAN CLEMENTE CA 92673 |
Dan W Gladney | director, officer: Chairman, President and CEO | 2800 PATTON ROAD, ST. PAUL MN 55113 |
Armistice Capital, Llc | 10 percent owner | 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
Armistice Capital Master Fund Ltd. | 10 percent owner | C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
Steven Boyd | 10 percent owner | 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
Sabby Management, Llc | 10 percent owner | 115 HIDDEN HILLS DR, SPICEWOOD TX 78669 |
Arda Phd Minocherhomjee | director | C/O CHICAGO GROWTH PARTNERS, 303 W MADISON ST., SUITE 2500, CHICAGO IL 60606 |
Scott P Youngstrom | officer: CFO and SVP, Finance | 2800 PATTON ROAD ST. PAUL MN 55113 |
Joseph Patrick Healey | 10 percent owner | 31 HUDSON YARDS, 10TH FLOOR, NEW YORK NY 10001 |
Healthcor Partners Ii, L.p. | 10 percent owner | 152 W. 57TH STREET, 43RD FLOOR NEW YORK NY 10019 |
Michael Y Mashaal | director | 309 WAVERLEY OAKS RD., SUITE 105 WALTHAM MA 02452 |
Healthcor Partners Fund Ii, L.p. | 10 percent owner | CARNEGIE HILL TOWER 152 WEST 57TH STREET, 43RD FLOOR NEW YORK NY 10019 |
Jeffrey C Lightcap | 10 percent owner | 152 W 57TH STREET 43RD FLOOR, NEW YORK NY 10019 |
Healthcor Partners Management Gp, Llc | 10 percent owner | 152 W 57TH STREET 43RD FLOOR, NEW YORK NY 10019 |
From GuruFocus
By Marketwired • 09-22-2023
By Marketwired • 09-14-2023
By Marketwired • 09-19-2023
By Marketwired • 08-07-2023
By Marketwired • 09-29-2023
By Marketwired • 08-03-2023
By sperokesalga sperokesalga • 03-22-2023
By Tiesvg Tiesvg • 12-22-2022
By Marketwired • 06-28-2023
By Marketwired • 09-21-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.